Cutler Group LP Denali Therapeutics Inc. Transaction History

Cutler Group LP

$307 Million
Q1 2024

A detailed history of Cutler Group LP transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Cutler Group LP holds 400 shares of DNLI stock, worth $9,672. This represents 0.0% of its overall portfolio holdings.

Number of Shares

400

Previous 400 -0.0%

Holding current value

$9,672

Previous $8,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 18, 2024	BUY	$16.2 - $23.18 $6,480 - $9,272	400 New	400 $8,000
Q1 2023 May 01, 2023	SELL	$21.91 - $32.67 $36,151 - $53,905	-1,650 Reduced 73.33%	600 $13,000
Q4 2022 Feb 07, 2023	BUY	$26.28 - $33.92 $38,106 - $49,184	1,450 Added 181.25%	2,250 $62,000
Q3 2022 Oct 25, 2022	BUY	$25.97 - $38.53 $3,116 - $4,623	120 Added 17.65%	800 $24,000
Q2 2022 Aug 04, 2022	SELL	$20.88 - $35.19 $12,945 - $21,817	-620 Reduced 47.69%	680 $20,000
Q1 2022 Apr 14, 2022	SELL	$29.0 - $47.27 $11,600 - $18,908	-400 Reduced 23.53%	1,300 $41,000
Q4 2021 Jan 18, 2022	BUY	$42.59 - $55.02 $22,998 - $29,710	540 Added 46.55%	1,700 $75,000
Q3 2021 Oct 26, 2021	BUY	$48.48 - $78.23 $27,148 - $43,808	560 Added 93.33%	1,160 $58,000
Q1 2021 Apr 26, 2021	SELL	$53.8 - $81.53 $45,192 - $68,485	-840 Reduced 58.33%	600 $34,000
Q2 2020 Jul 22, 2020	SELL	$16.01 - $28.82 $960 - $1,729	-60 Reduced 4.0%	1,440 $34,000
Q1 2020 May 07, 2020	BUY	$14.2 - $27.98 $14,200 - $27,980	1,000 Added 200.0%	1,500 $26,000
Q4 2019 Feb 06, 2020	BUY	$14.4 - $19.99 $5,760 - $7,995	400 Added 400.0%	500 $8,000
Q2 2019 Aug 09, 2019	BUY	$18.5 - $28.14 $1,850 - $2,814	100 New	100 $2,000
Q1 2019 May 10, 2019	SELL	$17.99 - $24.65 $1,798 - $2,465	-100 Closed	0 $0
Q4 2018 Feb 05, 2019	BUY	$13.88 - $21.75 $1,388 - $2,175	100 New	100 $2,000

Others Institutions Holding DNLI

# of Institutions

228

Shares Held

120M

Call Options Held

60.6K

Put Options Held

48.4K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.24B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.

Account